ALF召开疲劳研讨会,优先考虑患者关切并制定肝病研究议程

2026 年 11 月 20 日

Experts Discussed Fatigue as most Under-recognized Symptom of Liver Diseases

美国肝脏基金会(ALF) hosted a virtual workshop in late October titled, “Addressing Fatigue in Liver Diseases: From Unmet Need to Action.” This workshop brought together leading hepatologists, clinicians, researchers, and patient advocates to establish recommendations and an actionable plan that includes research initiatives, addresses patient care and support gaps, and identifies future initiatives to address fatigue in liver diseases. One clear theme emerged during the workshop – fatigue is one of the most significant and under-recognized symptoms across liver diseases but remains the most under-measured and under-treated symptom that’s typically not included in clinical guidelines. 

            “This virtual workshop was one of the first multidisciplinary fatigue-focused workshops ever convened by ALF,” said Lorraine Stiehl, Chief Executive Officer of American Liver Foundation. “The workshop provided a focused forum for stakeholders across the liver community and a fundable roadmap to improve the understanding, assessment and management of fatigue in liver diseases. Patients and clinicians shared their perspectives on the current state of the issue and identified the most pressing opportunities to advance care for those struggling with fatigue. ALF will produce a concise summary report to convene stakeholders, support pilot work and create educational resources and advocacy initiatives that provide greater awareness and improved outcomes for patients who experience fatigue in liver diseases.”

Workshop Highlights included:

  • Reviewed the current understanding of fatigue across liver diseases and the gaps in clinical and scientific knowledge. Determined that fatigue is the leading symptom across every liver disease category.
  • Multiple experts emphasized the lived experiences of patients and caregivers, including the impact of fatigue on quality of life, work, productivity, social participation, and independence across liver diseases including primary biliary cholangitis (PBC), 原发性硬化性胆管炎(PSC), 代谢功能障碍相关脂肪肝病(MASLD), metabolic dysfunction-associated steatohepatitis (MASH), 病毒性肝炎 和 肝硬化.
  • Multiple experts stressed that fatigue should not be dismissed as simply being tired. Ongoing discussions explored the growing evidence linking fatigue to inflammatory processes, brain signaling pathways, autonomic dysfunction, sleep disruption, and muscle metabolism.
  • Several researchers expressed concern that current guidelines continue to prioritize disease progression while often overlooking patient symptoms such as fatigue.
  • One clear outcome from the workshop is the need to  develop better ways to assess and measure fatigue symptoms. Fatigue questionnaires, fatigue timeline documentation, and fatigue surveys might be viable options for patients.
  • Multiple experts discussed practical interventions available now, even in the absence of approved drug therapies. They highlighted sleep management, exercise, lifestyle interventions, cognitive behavioral therapy, digital health tools, peer support and patient self-management.

             “There was broad enthusiasm about the opportunity to explore all of the recommendations and suggestions that would improve the lives of the 100 million Americans living with some form of liver disease, many of whom are also struggling with fatigue,” said Helene Jordan, PhD, National Senior Director, Research Program Management at American Liver Foundation. “ALF will translate the participants’ recommendations into a practical roadmap that connects the patient experience, clinical reality, and symptom science with patient-reported outcomes, trial designs, and basic research into the mechanisms of fatigue. ALF’s goal is to ultimately implement a viable program or research initiative that addresses this symptom that appears to be present in many patients who have liver disease. We also want to learn from other diseases that have fatigue as a concern such as rheumatoid arthritis, long COVID, fibromyalgia and many others.”

            American Liver Foundation gratefully acknowledges the following sponsors of this virtual workshop: Gilead, Ipsen, and Intercept/ALFASIGMA. Each sponsor’s incredible support made this insightful workshop possible.

            有关 ALF 的更多信息,请访问 www.liverfoundation.org。如果您对肝病有任何疑问或担忧,请于周一至周五上午 9 点至下午 5 点(美国东部时间)拨打我们的免费帮助热线 1-800-Go-LIVER (800-465-4837)。

关于美国肝脏基金会

American Liver Foundation (ALF) is a national community of patients, caregivers and medical professionals dedicated to helping people improve their liver health. Providing guidance and life-saving resources, we are a beacon for the 100 million Americans affected by liver disease. We advocate for patients and families, fund medical research, and educate the public about liver wellness and disease prevention. We bring people together through our educational programs and events and create a network of support that lasts a lifetime. ALF is the largest organization focused on all liver diseases and the trusted voice for patients and families living with liver disease. Celebrating 50 years of impact, leading the next 50 years forward.

交叉 LinkedIn Facebook Pins YouTube的 RSS twitter Instagram 空白 RSS-空白 空白 Pins YouTube的 twitter Instagram